Literature DB >> 6099638

Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.

P van der Marel, T G Hazendonk, M A Henneke, A L van Wezel.   

Abstract

The antigenic and immunogenic properties of poliovirus capsid polypeptides (VPs) have been investigated in vivo and in vitro. VPs were isolated from infectious and formalin inactivated virus. Upon immunization VPs from infectious virus did not induce neutralizing antibodies in laboratory animals after two or three injections. Monomeric VP1, VP2 and VP3 from formalin inactivated virus all induced high titres of neutralizing antibodies generally already after two injections. Some anti-VP sera neutralized heterologous virus types. All anti-VP sera reacted with the corresponding capsid polypeptides from the homologous and heterologous virus strains in an immunoblotting assay. The anti-VP sera reacted equally well with D- and C-antigen in ELISA. Our results indicate that not only VP1, but also VP2 and VP3 are involved in the induction of neutralizing antibodies.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6099638     DOI： 10.1016/0264-410x(83)90007-5

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  9 in total

1.  Molecular basis for linkage of a continuous and discontinuous neutralization epitope on the structural polypeptide VP2 of poliovirus type 1.

Authors:  K J Wiegers; K Wetz; R Dernick
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

2.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Authors:  B Blondel; R Crainic; O Fichot; G Dufraisse; A Candrea; D Diamond; M Girard; F Horaud
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

3.  Interaction of poliovirus with its purified receptor and conformational alteration in the virion.

Authors:  M Arita; S Koike; J Aoki; H Horie; A Nomoto
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure.

Authors:  T Herremans; J H Reimerink; T G Kimman; H G van Der Avoort; M P Koopmans
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

5.  Identification of a new neutralization antigenic site on poliovirus coat protein VP2.

Authors:  E A Emini; B A Jameson; E Wimmer
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

6.  Picornavirus-specific CD4+ T lymphocytes possessing cytolytic activity confer protection in the absence of prophylactic antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Isolation and immunizations with hepatitis A viral structural proteins: induction of antiprotein, antiviral, and neutralizing responses.

Authors:  J V Hughes; L W Stanton
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

8.  Establishment of a panel of in-house polyclonal antibodies for the diagnosis of enterovirus infections.

Authors:  Osamu Kotani; Naoko Iwata-Yoshikawa; Tadaki Suzuki; Yuko Sato; Noriko Nakajima; Satoshi Koike; Takuya Iwasaki; Tetsutaro Sata; Teruo Yamashita; Hiroko Minagawa; Fumihiro Taguchi; Hideki Hasegawa; Hiroyuki Shimizu; Noriyo Nagata
Journal:  Neuropathology       Date:  2014-09-28       Impact factor: 1.906

9.  Deconvolving mutational patterns of poliovirus outbreaks reveals its intrinsic fitness landscape.

Authors:  Ahmed A Quadeer; John P Barton; Arup K Chakraborty; Matthew R McKay
Journal:  Nat Commun       Date:  2020-01-17       Impact factor: 14.919
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.